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Abstract
Background: Chronic pain is a prevalent and distressing condition caused by an unceasing pain lasting more than 3 months or
a pain that persists beyond the normal healing time. There is evidence of inadequate management partly explained by the
unawareness regarding the magnitude of the problem.
Objectives: To estimate the annual expected costs and consequences of chronic pain caused by musculoskeletal diseases from
the health system perspective in Chile.
Methods: AMarkov cohort model was built to represent chronic pain and estimate expected costs and consequences over 1-year
time horizon. Transition probabilities were obtained through expert elicitation. Consequences examined were: years lost to
disability (YLD), depression, anxiety, and productivity losses. Direct health care costs were estimated using local sources.
Probabilistic sensitivity analysis was performed to characterize second-order uncertainty.
Results: The annual expected cost due to musculoskeletal chronic pain was estimated in USD $1387.2 million, equivalent to
0.417% of the national GDP. Lower back pain and osteoarthritis of the knee explained the larger proportion of the total cost, 31.8%
and 27.1%, respectively. Depression attributed to chronic pain is another important consequence accounting for USD $94 million
(Bayesian credibility interval 95% $49.1–$156.26). Productivity losses were also important cost, although early retirement and
presenteeism were not measured. Chronic pain causes 137,037 YLDs.
Conclusion: Chronic pain is not only an important cause of disability but also responsible for high social and financial burden in
Chile. Public health programs focused on managing chronic pain may decrease burden of disease and possibly reduce costs.
Keywords: Chronic pain, Cost, Economic evaluation, Chile
1. Introduction
Chronic pain has been defined as an unceasing pain lasting more
than 3 months or a pain that persists beyond the normal healing
time.18 It is a multifactorial condition that manifests with physical
and psychological symptoms causing multiple consequences,
including the decrease in quality of life, changes in mood,
impaired function, sleep disturbance, and altered appetite among
many others.35 Chronic pain due to musculoskeletal (MSK)
disorders is a frequent condition affecting almost 20%14 of the
world’s population. In Europe, it was estimated that 19% reported
a moderate to severe intensity of pain, many of which did not
receive appropriate medical care and almost 40% would receive
inadequate treatment.4 In Latin America, the prevalence ranges
from 16.8% to 40.3%.28
In general, there is consensus among clinical experts that
treating chronic pain is complex mainly because of the co-
existence and interaction of biological, psychological, and social
factors. This context explains inadequate responses to mono-
therapies requiring a comprehensive multimodal and multidisci-
plinary management. In addition, it has been argued that a lack of
knowledge on the physiopathology and management of chronic
pain increases the need of trained health professionals with
specific skills to treat chronic pain, which ultimately leads to
patients being treated inadequately as if they were suffering an
episode of acute pain. Moreover, the use of opioids is still
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influenced and limited by medical, ethical, cultural, and legislative
factors that lead to a weak prescription, subdosage, and poor
adhesion.4 There is also a generalized concern regarding the
availability of guidelines for the management of chronic pain.
Despite these guidelines exist, there are only few of them
available;many are very specific; and it has been observed scarce
implementation in routine clinical practice.
Furthermore, chronic pain is usually considered a symptom
secondary to another disease, which leads health professionals
to be highly focused on the treatment of the primary aetiology.
However, inmany cases, the unwanted consequences of chronic
pain, such as decreased quality of life and disability, depend
exclusively on the pain domain and, hence, require management
that relies largely on pain-specific measures. In addition, treating
and managing the aetiology of certain conditions does not
necessarily result in a solution to the problem of chronic pain. For
example, although hip replacement is the best treatment for
severe hip osteoarthritis (OA) and most patients recover mobility,
some remain with chronic pain. Thus, addressing chronic pain as
a health problem seems clinically reasonable.
From a public health perspective, chronic pain is a prevalent
problem associated with high burden of disease and elevated
costs. Several studies have estimated the economic impact of
chronic pain from different perspectives and using different
approaches and/or methodologies. Some have looked into the
financial implications of chronic pain as a general condition, and
others have focused on specific prevalent pathologies associated
with chronic pain. For example, in the United States, chronic pain
costs were estimated higher than those for heart disease,
diabetes, or cancer.20 Other European countries such as Ireland,
Sweden, the United Kingdom, andGermany have also attempted
estimating costs with the aim of revealing the magnitude of this
health problem. However, it still remains uncertain the economic
impact of chronic pain on developing countries where the
provision of health services is more limited.
On the side of health consequences of chronic pain, there is
more consensus and much more has been described in the
literature. More broadly, in terms of burden of illness, the Global
Burden of Disease (GBD) study stated that MSK disorders were
responsible for more than 120 million years lived with disability
(YLDs) and account for more than 21% of the worldwide
disability.13,22 However, it remains unknown the role of the pain
domain on this disability estimate. In a recently published study in
Chile, the burden of MSK disorders associated with chronic pain
was the first cause of burden.42
Chile is an upper-middle-income country that provides limited
coverage tomanage chronic pain. Furthermore, the incorporation
of new services to the coverage scheme is driven by an evidence-
based priority setting process, where burden of disease, financial
burden on families, and other health consequences are relevant
criteria to be considered. To contribute to the priority setting
process, we performed a cost–consequence type economic
evaluation to characterize health and nonhealth costs due to
chronic pain in Chile. More specifically, this study aimed to
estimate the expected annual cost as well as the magnitude of
depression, anxiety, disability, and productivity loss attributable
to pain related to MSK disorders.
2. Methods
The expected cost and consequences were estimated using
mathematical modelling. We implemented a de novo state
transition Markov model to characterize changes in severity over
time.We focused on pain related toMSK disorders because of its
high prevalence allowing us to capture most of the associated
economic and health burden. In addition, given the epidemio-
logical and administrative data available as well as the relevance
for public health, we restricted the analysis to 6 MSK diseases.
The selection of these pathologies was submitted for consider-
ation and agreed by a panel of experts, consisting of a group of
specialists of the areas of anaesthesiology, traumatology,
palliative care, rheumatology, and physiotherapy. The selection
of the panel of experts was supported by the executive board of
the Chilean Association for the Study of Pain (ACHED), the
leading local scientific society that gathers a multidisciplinary
group of experts with interest in the study and treatment of pain.1
The selected pathologies were: (1) OA of the knee; (2) OA of the
hip; (3) lower back pain (LBP); (4) chronic shoulder pain (CSP); (5)
myofascial syndrome (MFS); and (6) fibromyalgia (FM). Although
FM is possibly a disease of the central nervous system and
peripheral nervous system, it was considered relevant to the
analysis as the pain it produces is expressed as chronic MSK
pain. There was consensus among experts that MFS was
a relevant and common MSK health problem leading to chronic
pain, often misdiagnosed, poorly managed, and that less is
known among health care professionals, hence it was considered
important for this analysis.
2.1. Mathematical model
To estimate the costs and consequences, a mathematical model
was built in Excel (Fig. 1) to represent the natural history of chronic
pain. To differentiate the different possible health states within
chronic pain, we implemented the most common way that the
patients are assessed based on the severity/intensity of pain
through the visual analogue scale (VAS).15 Hence, the model was
implemented defining 4 health states: (1) mild chronic pain, (2)
moderate chronic pain, (3) severe chronic pain, and (4) death from
other causes. The model assumes that patients do not die
because of this cause (chronic pain), meaning that health loss is
given mainly from a decrease in quality of life. It also assumes that
patients transit between Markov states independently of their
aetiologies. The structure of the model and assumptions were
discussed in an advisory meeting where the panel of experts
validated the model.
Figure 1. Markov model to represent chronic pain. The figure represents the
natural history of chronic pain where patients transit through a 4-state Markov
model. The 4 health states that make up the model are based on the intensity
of pain: mild, moderate, severe, and death from other causes. Patient’s transit
through the model irrespective of the pathology of origin based on the
transition probabilities obtained through an expert elicitation exercise.
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For the purposes of this study, chronic pain was defined as an
unceasing pain lasting more than 3 months or a pain that persists
beyond the normal healing time, which usually has no protective
function, impairs health, and causes disability in patients who
suffer it.18 Health states were defined based on intensity revealed
by the VAS15:
1. Mild chronic pain (VAS 1–3): Quality of life of patients is not
affected. They can perform daily living activities without
difficulty. Functionality and mobility is preserved, and work
productivity is not affected.
2. Moderate chronic pain (VAS 4–6): Quality of life of patients
as well as work productivity is affected mild to moderately.
In this category, the perception of patients becomes more
important, and it is expected that those who perceive pain
see their quality of life and work productivity affected
moderately. Therefore, they are expected to consult more
than those who perceive mild pain.
3. Severe chronic pain (VAS 7–10): Quality of life and work
productivity are severely affected. Mobility and functional
capacity are impaired, and self-care activities cannot be
performed or with difficulty.
The cohort of patients with chronic pain entered into the model
to one of the 3 possible abovementioned health states. The initial
allocation of patients to each health state by pathology (except
MFS) in the model was obtained from the 2010 National Health
Survey (NHS) based on the proportion of patients who reported
intensity of chronic pain.19,25 Because MFS was not assessed in
the NHS, the initial distribution of patients (at time 0) was assigned
based on expert consensus. This approach was preferred to an
international estimate because it was more feasible to be
accepted for local policy-making. It was suggested that between
5% and 10% of patients (average 7.5%) see a specialist when the
intensity of pain is classified asmild, 35%consult whenmoderate,
and 60% when severe. After entering the model, patients could
transit between health states according to transition probabilities.
This was considered a reasonable approach, as it is expected
that patients with chronic pain, depending on the current
management, will see their health status improved or worsened
as reflected by the intensity of pain. For example, a patient
suffering from mild chronic pain may progress to moderate,
severe, remain mild, or die from other causes (Fig. 1). This
transition occurs assuming the usual/current pharmacological
and nonpharmacological management that an average Chilean
patient receives. A 1-month length cycle was modelled, as it was
considered a reasonable period to characterize significant
changes. It should also be noted that transition probabilities
remain constant over time and are not dependant on the aetiology
originating chronic pain.
The Chilean cohort of patients was estimated based on the
reported prevalence of each MSK disorder obtained from the
NHS25 (Table 1). It was assumed that all prevalent cases have an
actual diagnose, although it is expected that a proportion of those
suffering mild and moderate chronic pain will not consult. A
sensitivity analysis was performed exploring the impact on the
results when 50% of patients with mild and 25% of patients with
moderate chronic pain have not been diagnosed.
2.2. Transition probabilities
Given the lack of data in the published literature to estimate
transition probabilities for this model, they were obtained through
an expert elicitation exercise as suggested by Soares et al.33 This
methodology allows not only to obtain the expected probability
value but also the underlying uncertainty revealed by experts.
Hence, the average probability was accompanied by an empirical
probability density distribution built from a 21 3 21-squared
matrix. These probabilities were estimated based on a 6-question
survey completed by a total of 13 clinical experts (anaesthesiol-
ogist, traumatologists, and rheumatologists). Each expected
probability corresponds to the weighted average obtained from
the joint distribution of all experts considering the total of available
options per question (21 3 13 5 273 per question). Finally, the
probability of death was obtained from the mortality series
reported by the Department of Epidemiology at the Ministry of
Health.26 The annual mortality (5.1 per 1000 inhabitants) was
converted to a monthly mortality (0.42 per 1000 population) to fit
the model assuming that death occurs at a constant instanta-
neous rate. This method allows to estimate a Bayesian credibility
interval that is largely more appropriate to make inference and
more intuitive for decision-making.
2.3. Consequences
A literature review was conducted to identify the most relevant
consequences of chronic pain. The list of consequences
summarized in Table 2 was then assessed by the panel of
experts based on available data and their impact on health. At
last, 4 consequences were considered in the analysis: disability,
depression, anxiety, and productivity loss. Disability was mea-
sured as YLDs assuming that there is no mortality attributed to
pain. Years livedwith disability represent the equivalent number of
years spent with disability that are estimated using the incidence,
disease duration (in years), and corresponding disability weight.
The latter ranges from 0 to 1 and reflects the severity of the
disease, where 0 represents perfect health and 1 represents
disability equivalent to death.36 The disability weights were
obtained from the GBD study32 and adjusted to represent the
pain domain of disability. Depression and anxiety were measured
as prevalence of patients where the cause was attributed to
chronic pain. For depression, it was possible to calculate the
population attributable fraction (PAF), which corresponds to the
proportion of cases of a disease that can be avoided in a given
population if a given risk factor was not present.39 For this
purpose, data from the 2010 NHS were used to estimate this
parameter for all diseases except MFS. For the latter, a literature
review was conducted to obtain the proportion of patients who
had moderate or severe pain and also had depression (not
necessarily attributed to pain).41 It was also assumed that
patients with mild pain could suffer from depression associated
but not attributable to chronic pain.12 This was considered
reasonable, as most mild chronic pain cases may develop
depression due to other causes other than pain. For anxiety,
a literature review was conducted to estimate the proportion of
patients in the whole population with anxiety and chronic pain.41
Finally, productivity losses were measured as monetary costs
following the human capital approach. This method is based on
the association between productive time and health.9 Thus,
absenteeism can be perceived as a loss of investment that
a society incurs because an individual has less productive
capacity. This methodology suggests that a good proxy to
productivity loss is the average market wage. We analysed the
2014 to 2015 private sector medical leave database to estimate
the total number of medical leaves per MSK disease. This
database includes all possible diagnoses according to the
International Classification of diseases 10th version (ICD-10) of
theWorld Health Organization.40 The use of this database implied
the assumption that patients treated in the private sector (approx.
18% of the Chilean population) are equivalent to that of the public
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Table 1
Model parameters and parametric distributions.
Item Value SE Distribution Reference
Prevalence*
Knee OA 5.30% 0.46% Beta 2009–2010 NHS27
Hip OA 1.70% 0.26% Beta
FM 1.10% 0.20% Beta
Shoulder pain 4.00% 0.36% Beta
LBP 6.20% 0.61% Beta
MFS 0.90% 0.01% Beta
Initial distribution based on the 2009/2010 NHS
OA of the knee (prevalent population:
760,015)
Mild 38.90% 295,646 Dirichlet 2009–2010 NHS27
Moderate 29.60% 224,965 Dirichlet
Severe 31.50% 239,405 Dirichlet
OA of the hip (prevalent population: 243,779)
Mild 55.90% 136,272 Dirichlet 2009–2010 NHS27
Moderate 19.70% 48,024 Dirichlet
Severe 24.40% 59,482 Dirichlet
FM (prevalent population: 157,739)
Mild 5.17% 8,161 Dirichlet 2009–2010 NHS27
Moderate 15.46% 24,392 Dirichlet
Severe 79.36% 125,186 Dirichlet
Shoulder pain (prevalent population:
573,597)
Mild 5.60% 32,121 Dirichlet 2009–2010 NHS27
Moderate 42.60% 244,352 Dirichlet
Severe 51.80% 297,123 Dirichlet
LBP (prevalent population: 889,075)
Mild 7.14% 63,474 Dirichlet 2009–2010 NHS27
Moderate 44.44% 395,134 Dirichlet
Severe 48.42% 430,467 Dirichlet
MFS (prevalent population: 129,059)
Mild 7.50% 9,679 Dirichlet Experts input (point estimate)
Moderate 32.38% 41,783 Dirichlet
Severe 60.13% 77,597 Dirichlet
Transition probabilities†
Mild-moderate 18.41% N/A Bootstrap‡ Expert elicitation exercise (point estimate)
Mild-severe 10.70% N/A Bootstrap‡
Moderate-severe 27.38% N/A Bootstrap‡
Moderate-mild 55.55% N/A Bootstrap‡
Severe-mild 33.15% N/A Bootstrap‡
Severe-moderate 59.14% N/A Bootstrap‡
Probability of death 0.04% 0.005% Beta 21
Costs (USD per month)
Depression $12.1 $1.5 Gamma 29
Anxiety $11.8 $1.5 Gamma 29
OA of the knee
Treatment mild $7.5 $1.0 Gamma Point estimate
Treatment moderate $18.4 $2.4 Gamma Point estimate
Treatment severe $97.7 $12.5 Gamma Point estimate
Absenteeism $989.9 $896.3 Gamma Point estimate
OA of the hip
Treatment mild $7.6 $1.0 Gamma Point estimate
Treatment moderate $18.4 $2.4 Gamma Point estimate
Treatment severe $97.7 $12.5 Gamma Point estimate
Absenteeism $1,184.0 $923.1 Gamma Point estimate
FM
Treatment mild $4.7 $0.6 Gamma Point estimate
Treatment moderate $14.2 $1.8 Gamma Point estimate
Treatment severe $97.0 $12.4 Gamma Point estimate
Absenteeism $438.9 $560.6 Gamma Point estimate
Shoulder pain (CSP)
Treatment mild $8.0 $1.0 Gamma Point estimate
Treatment moderate $21.2 $2.7 Gamma Point estimate
Treatment severe $79.5 $10.1 Gamma Point estimate
Absenteeism $797.5 $860.7 Gamma Point estimate
(continued on next page)
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sector (approx. 82% of the Chilean population). We are aware
that this estimate might be a source of underestimation because
these MSK problems are more prevalent in population insured in
the public sector. Althoughmore prevalence does not necessarily
mean more absenteeism, we did not have access to data from
the public sector. We adopted a societal perspective; hence, all
costs were measured, including those bared by the patient.
Figure 2 summarizes the consequence structure as assumed in
the model. Data were analysed using STATA 13.
2.4. Costs
Costs were identified, measured, and valued.8 Health resources
were identified (ie, doctor visits, physiotherapy sessions, type of
treatment, etc) and measured (quantity and frequency of use of
each health resource) from different sources including interna-
tional and local clinical guidelines, expert estimates as well as the
cost study27 performed by the Ministry of Health every 3 years to
estimate the annual premium per beneficiary in the context of the
universal coverage health benefit plan (GES). The latter source
was most relevant to estimate the cost of OA of the knee and hip,
as they are financed through the GES plan and have associated
specific health resources for the general management and
treatment. All these sources are recommended in the economic
evaluation guideline elaborated by theMinistry of Health.24 To put
a monetary value to each health resource, “the published public
payer (FONASA) annual tariff10 and the 2011 Health Resources
Cost Study” requested by FONASA6 were used. For pharma-
ceuticals not included in any of these data sources, the average
price was requested to the institution responsible for the
purchasing of national health supplies, which provided the
average price for 2015. This process allowed for the construction
of baskets of health resources that were built for all 6 MSK
disorders as well as for each consequence (depression, anxiety,
and disability), which were then validated by experts.
It was assumed that all the clinical management of each MSK
disease was intended for pain relief and hence, was a good proxy
to quantify the impact of disability related to pain as a conse-
quence. The costing of each MSK disease required the
identification and gathering of health resources according to the
Table 1 (continued)
Model parameters and parametric distributions.
Item Value SE Distribution Reference
LBP
Treatment mild $4.7 $0.6 Gamma Point estimate
Treatment moderate $18.8 $2.4 Gamma Point estimate
Treatment severe $82.6 $10.5 Gamma Point estimate
Absenteeism $602.7 $631.7 Gamma Point estimate
MFS
Mild problem treatment $4.7 $0.6 Gamma Point estimate
Moderate problem treatment $17.2 $2.2 Gamma Point estimate
Severe problem treatment $97.2 $12.4 Gamma Point estimate
Consequences
Pain domain DW OA of the knee 0.0239 0.0028 Beta Global Burden of Disease study8
Pain domain DW OA of the hip 0.0239 0.0028 Beta
Pain domain DW FM 0.0815 0.0399 Beta
Pain domain DW shoulder pain 0.0239 0.0028 Beta
Pain domain DW LBP 0.0845 0.0107 Beta
Pain domain DW MFS 0.0486 0.0020 Beta
Anxiety associated with chronic pain 5.3% 0.7% Beta Study that reveals the association between anxiety
and chronic pain41
PAF-Depression§ (FM) 87.7% 11.2% Beta 2009-2010 NHS27
PAF depression CSP 86.4% 11.0% Beta
PAF depression LBP 83.7% 10.7% Beta
PAF depression MFS 33.0% 4.2% Beta
* Estimated population based on .15 years NHS considering 2015 projections (14,339,915).
† Transition probability of remaining in a health corresponds to 1 minus the probability of transiting and a Beta distribution was assigned.
‡ Boostrap refers to a random sampling with replacement based on the empirical distribution obtained from the EEX exercise.
§ Only moderate to severe intensity of pain may have attributable depression.
CSP, chronic shoulder pain; DW, disability weight; EEE, expert elicitation exercise; FM, fibromyalgia; LBP, lower back pain; MFS, myofascial syndrome; NHS, National Health Survey; OA, osteoarthritis; PAF, population
attributable fraction.
Table 2
Health and non-health consequences associated with chronic pain.
General aspects Physical health Mental health Societal implications
Quality of life Physical symptoms Fear Decrement in social skills
Negative disease impact Pain intensity* Fear to pain Social skills at work
Site of pain Avoid movements due to fear of pain Absenteeism
Physical functionality Depression Change in employment status
General disability Anxiety Presenteeism
Pain-related disability Psychological distress
Behavioural change
Adaptive disorder
* Measured as VAS or decrease in the use of analgesics.
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4-health state model structure. Four main cost categories were
identified: (1) medical visits, (2) pharmacological treatment,
(3) physiotherapy, and (4) hospitalization. It was assumed that
only a proportion of patients with severe chronic pain may require
hospitalization for this purpose. The most common reason is
exacerbations of chronic pain, which are generally severe,
disabling, with no specific related cause, and generally requiring
multiple admissions.23,38 The usual pharmacologic treatment
used on an outpatient basis by patients in Chile was obtained
from a previously validated and published population-
representative telephone survey.29 This information was com-
plemented and validated by experts.
Finally, the same database and assumptions were used to
estimate productivity loss as cost. In this case, only the costs
bared by the health system were considered; therefore, we
calculated only the proportion of days payed by the health
system. In most cases, it does not correspond to 100% of the
approved number of days established in the medical leave.
All costs were measured in 2015 Chilean pesos and converted
to US dollars (USD) using 2015 purchasing power parities (1 USD
5 394.35 Chilean pesos).30
Years lived with disability correspond to the equivalent number
of years spent with maximum disability (equivalent to death). This
metric requires incidence data, disease duration in years, and
a disability weight, which reflects the severity of the diseasewhere
0 represents perfect health and 1 represents disability equivalent
to death.36 The disability weights were obtained from the GBD
study32 and adjusted to represent the pain domain of disability.
Two other relevant consequences identified corresponded to
mental disorders, depression, and anxiety. The aim was to
estimate the prevalence of patients with depression and/or
anxiety with selected MSK disorders where the cause was
attributed to chronic pain. For depression, it was possible to
calculate the PAF, which corresponds to the proportion of cases
of a disease that can be avoided in a given population if a given
risk factor was not present.39 Data from the 2010 NHSwere used
to estimate this parameter for all diseases except MFS. For the
latter, a literature review was conducted to obtain the proportion
of patients who had moderate or severe pain and also had
depression.41 It was also assumed that patients with mild pain do
not have depression attributable to chronic pain. In addition,
patients with moderate or severe chronic pain can develop
mild or moderate depression (not major). A literature review
was also conducted to estimate the proportion of patients in
the whole population with anxiety and chronic pain.41 Finally,
productivity losses were measured as monetary costs follow-
ing the human capital approach. This method is based on the
fact that the association between productive time and health9
is the average market wage. The 2014 to 2015 private sector
medical leave database was examined to estimate the total
number of medical leaves according to the International
Classification of diseases 10th version (ICD-10) of the World
Health Organization.40 It was assumed that medical leaves in
the private sector (approx. 18% of the Chilean population) are
equivalent to that of the public sector (FONASA approx. 82% of
the Chilean population), given we had no access to the latter.
Data were analysed using STATA 13.
2.5. Sensitivity analysis
A 1-way deterministic sensitivity analysis was performed to
determine the effect of variations of one parameter on the results,
ceteris paribus. All model parameters were tested through
a 1-way sensitivity analysis. Furthermore, to characterize
second-order uncertainty, a probabilistic sensitivity analysis was
performed using Monte Carlo simulations (5000 iterations).
Parametric distributions were assigned to all parameters accord-
ingly (Table 1).
Figure 2. Schematic representation of costs and consequences of chronic pain. The figure represents the structure of this cost–consequence study. It identifies
the cost components as well as the health and nonhealth consequences of chronic pain because of MSK disorders. MSK, musculoskeletal; OA, osteoarthritis;
YLD, year lived with disability.
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3. Results
The expected costs per month for the therapeutic management
of mild, moderate, and severe chronic pain per patient were USD
$63.5, USD $101.82, and USD $734.5, respectively. The higher
cost of severe chronic pain is mainly explained by the high
probability (90%) that patients require an emergency department
visit while suffering severe chronic pain, which, in some cases,
also leads to hospitalization.
Table 3 report the point estimate and its 95% Bayesian
credibility interval following 5000 Monte Carlo simulations. The
results reveal important uncertainty around point estimates,
which is reflected through the wide credibility interval. The annual
expected cost for the 6 pathologies reached $1387.2 MM (ICB
95% $792.71 MM and $2274.6 MM). This amount corresponds
to what the health system (public and private) in Chile annually is
expected to incur for the management of these 4 chronic pain
consequences. This result assumes that all prevalent cases have
an actual diagnose. When assessing a different scenario where
50% of patients with mild and 25% of patients with moderate
chronic pain are not diagnosed, the total expected cost drops to
$1095.89 MM, thus decreasing by 21%.
Of the MSK diseases studied, LBP and OA of the knee
generate the highest costs, occupying 31.8% and 27.1% of the
total expected costs, respectively. For each MSK disease, the
main chronic pain cost component was disability. The distribution
of this cost comprises mainly of physiotherapy (32.4%) and
medical visits (41.7%) followed by hospitalization (21.1%) and
medications (4.8%). For example, out of the total estimated cost
per pathology, 97.32% of OA of the knee, 96.96% of OA of the
hip, and 88.94% of MFS correspond to the therapeutic
management of chronic pain, our proxy to disability. A proportion
of the total cost is due to chronic pain attributed depression
reaching approximately 17% and 16% of FM and CSP, re-
spectively. It should be noted that it was not possible to estimate
the cost/consequence associated with the productivity loss due
to MFS because it is not identifiable through ICD-10 code.
In terms of consequences, both, LBP andOAof the knee, were
themost disabling conditions associatedwith 78,137 and 19,068
YLDs, respectively, whichwere explained only by the pain domain
of disability. In total, the pain domain is responsible for 137,037
(ICB 95% from 69,873–243,523). Years lived with disability in
patients diagnosed with these 6 MSK diseases. When assessing
depression and anxiety, the higher annual costs were driven by
LBP and CSP reaching $75.20 MM and $50.26 MM with
a prevalence of 2.06% and 1.38%, respectively. Notably,
because the PAF of OA knee and hip were assumed zero, no
cases of depression attributable to chronic pain were estimated.
Similarly, the estimated anxiety costs are correlated with the
prevalent population.
Table 3
Probabilistic sensitivity analysis: point estimates and 95% BCI for costs and consequences of MSK disorders.
MSK disorder Consequence Costs ($USD) Consequence Consequence unit
Point estimate 95% BCI Point estimate 95% BCI
OA of the knee Disability $366,211,637 $210,133,912 $600,594,672 19,068 10,304 33,092 YLDs
Depression $0 $0 $0 N/A N/A N/A Prevalence (%)
Anxiety $1,411,872 $748,375 $2,427,589 0.7934% 0.7871% 0.7996% Prevalence (%)
Productivity loss $8,686,099 $3,780,118 $17,975,001 $13,200,758 $5,744,861 $27,317,630 USD
Subtotal $376,309,608 $214,662,405 $620,997,261 N/A N/A N/A N/A
OA of the hip Disability $115,327,355 $61,457,692 $200,502,632 6,049 2,967 10,898 YLDs
Depression $0 $0 $0 N/A N/A N/A Prevalence (%)
Anxiety $440,134 $219,754 $788,895 0.7728% 0.7661% 0.7796% Prevalence (%)
Productivity loss $3,178,121 $1,297,813 $6,711,842 $4,507,973 $1,840,870 $9,520,343 USD
Subtotal OA hip $118,945,610 $62,975,260 $208,003,369 N/A N/A N/A N/A
FM Disability $64,114,762 $33,044,781 $109,308,536 12,875 2,842 32,351 YLDs
Depression $13,428,148 $6,373,196 $23,759,407 35.37% 35.07% 35.67% Prevalence (%)
Anxiety $279,496 $133,663 $513,152 0.7570% 0.7502% 0.7639% Prevalence (%)
Productivity loss $1,042,287 $426,977 $2,227,564 $2,175,964 $891,392 $4,650,447 USD
Subtotal FM $78,864,693 $39,978,618 $135,808,660 N/A N/A N/A N/A
Shoulder pain Disability $257,303,240 $153,304,388 $413,319,876 14,325 7,984 24,306 YLDs
Depression $49,194,086 $26,150,207 $81,372,315 35.73% 35.47% 35.99% Prevalence (%)
Anxiety $1,069,980 $590,444 $1,790,866 0.7980% 0.7921% 0.8038% Prevalence (%)
Productivity loss $231,616 $96,483 $493,837 $469,809 $195,707 $1,001,698 USD
Subtotal CSP $307,798,922 $180,141,523 $496,976,895 N/A N/A N/A N/A
LBP Disability $359,755,836 $212,646,986 $576,887,066 78,137 41,790 132,486 YLDS
Depression $73,539,627 $38,711,883 $121,423,015 34.35% 34.10% 34.60% Prevalence (%)
Anxiety $1,663,164 $881,588 $2,835,849 0.8020% 0.7959% 0.8081% Prevalence (%)
Productivity loss $6,096,224 $2,951,983 $11,729,315 $13,310,534 $6,445,379 $25,609,857 USD
Subtotal LBP $441,054,851 $255,192,441 $712,875,245 N/A N/A N/A N/A
MFS Disability $57,109,506 $35,649,768 $88,459,238 6,582 3,987 10,390 YLDs
Depression $6,839,461 $3,979,210 $11,072,715 22.03% 21.89% 22.17% Prevalence (%)
Anxiety $241,558 $133,556 $403,176 0.8000% 0.7943% 0.8056% Prevalence (%)
Productivity loss N/A $0 $0 N/A N/A N/A USD
Subtotal MFS $64,190,525 $39,762,534 $99,935,128 N/A N/A N/A N/A
Total 6 MSK disorders $1,387,164,208 $792,712,780 $2,274,596,559 N/A N/A N/A N/A
BCI, Bayesian credibility interval; CSP, chronic shoulder pain; FM, fibromyalgia; LBP, lower back pain; MFS, myofascial syndrome; MSK, musculoskeletal; N/A, not applicable; OA, osteoarthritis; USD, US dollar; YLD, year lived
with disability.
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An important consequence of chronic pain is given by the loss
of productivity. Themagnitude of this consequence is determined
by the prevalent population and the average number of days of
medical leave associated with each diagnose. Lower back pain
and OA of the knee produce the largest productivity losses
accounting for USD $13.31 MM and USD $4.51 MM per year,
respectively. Out of these, only a proportion is incurred by the
health system (the cost of productivity loss).
4. Discussion
Chronic pain is a common public health problem that causes
considerable disability, impaired quality of life, and several other
undesired negative consequences. The way that most health
systems have addressed this public health problem is mainly
through the implementation of strategies focused on the clinical
management of the primary aetiology lacking a more compre-
hensive treatment with a focus on chronic pain. This study
produced an estimate of the expected annual cost and a set of
consequences attributable to chronic pain, which aims to
contribute to the characterization of chronic pain as a public
health problem. This is, to the best of our knowledge, the first
study of its kind in Latin America.
Lower back pain and OA of the knee were the 2 most costly
diseases occupying 31.84% and 26.88% of the total expected
costs, respectively. The cost attributed to the management of the
disease, our proxy to disability, accounted for most of the total
cost. In terms of YLDs, the role of the pain domain was critical
leading to 131,559 YLDs in patients diagnosed with these 6 MSK
diseases. As a reference, in Chile, the last nationwide burden of
disease study (2008), which did not include low back pain or
MFS, revealed that the first cause of burden was hypertensive
disease that accounted for 257,814 disability-adjusted life years.
Thus, only the pain domain of these 6 MSK diseases explains
more than half of the disability associated with the main cause of
burden in Chile. This can be complementedwith recent published
data showing that YLDs are lostmostly during productive ages for
many MSK diseases.42
The results of this study differ from some reported in the
literature where an important component of the total cost relied
on productivity loses.7,17 On average, costs due to productivity
losses accounted for 4% only. This can be partly explained by the
fact that we could assess reported medical leaves for the private
sector, which comprises only 18% of the total population. Hence,
assumptions had to be made regarding the remaining 82%,
which probably underestimates the total expected costs. In fact,
out of the total medical leaves during 2015, 57% corresponded to
the public sector and 43% to the private sector. Further analysis is
required on availability of data from the public sector.
In terms of total direct cost of chronic pain in Chile relative to the
GDP, 0.417% is spent on chronic pain due to MSK, which is
smaller than what has been published elsewhere.5,7 Several
reasonsmay explain this difference. The health care structure and
relative low cost of human resources within the health care
system compared with Europe may be one reason to explain the
differences in the results. Nevertheless, the differences may be
also explained because of the lack of information on medical
leaves from the public sector, and numerous diseases causing
chronic pain that were not within the scope of the analysis.
Published studies used different methodologies to estimate
the cost of chronic pain. The most frequent was the use of a top-
down approach of patients or national health surveys to capture
the incremental cost of chronic pain compared with patients
diagnosed with the same basal disease but not suffering chronic
pain.5,7,16 Although methodological differences limit the compa-
rability of results, other studies have found similar results in terms
of public health expenditure of chronic pain or associated
diseases in Europe. For example, the economic impact of
chronic pain in Portugal showed that costs reached 2.71% of
annual GDP.2 Similarly, in 2012 in Ireland, the economic impact in
terms of GDP reached 2.86%.31 Evidence from Sweden, while
also revealing a high economic impact, they also highlighted the
relevance of productivity loses in those unable to work because of
pain or early retirement.11 More specifically, the United Kingdom
and Germany estimated the overall cost of back pain which alone
reached 1.5% and 2.2% of annual GDP, respectively.21,37 As
mentioned before, we did not identify published evidence in Chile
or Latin America reporting the costs and consequences of
chronic pain using similar methodologies.
In addition, there are 2 possible consequences that were not
measured: early retirement and presenteeism. Although the
former corresponds to the retirement before the legal age
because of the disability related to chronic pain, the latter refers
to the decrements in productivity because of a health problem in
workers who continue attending their jobs. These consequences
have a direct impact on patients and society. However, in Chile,
the costs associated with these 2 problems do not fall in the
health system budget; therefore, excluding them is consistent
with our analysis that adopts the health system perspective.
One important limitation regarding productivity costs and
consequences is that our estimates do not capture nor
characterize medical leaves of patients diagnosed with MFS.
Unfortunately, to date, this important health problem has not
been classified by the ICD-10, and therefore, it cannot be
identified in the corresponding database. However, as it
corresponds to a very specific diagnose and physicians are still
not trained correctly to identify it, part of it could be possibly
assumed as other diagnoses such as FM. The magnitude of this
is unknown, and it is not possible to determine the magnitude
based on available data. A possible solution relies on the still
ongoing development of the new classification for chronic pain to
be included in the upcoming 11th revision of the ICD.34 This will
allow us to study chronic pain as a whole and enhance the
development of guidelines to support a specialized chronic pain
treatment.
Another limitation is that our study does not consider all MSK
diseases causing chronic pain. For example, epicondylitis and
cervical pain are 2 prevalent diagnoses that were not evaluated
but have also shown to cause significant costs and consequen-
ces attributed to chronic pain. On the other hand, when
considering mental health problems, adjustment disorder is one
of the most commonly described in these patients, and it is
probably attributed to chronic pain. However, because of the
difficulty in obtaining the required data, it was not possible to
consider this important result in our analysis.
One general limitation of our study was the availability of data,
hence the use of assumptions and expert opinion to be able to
conduct the evaluation, which we acknowledge is not considered
high-level evidence. However, it should be noted that there is an
increasing consensus that mathematical modelling is an ade-
quate instrument to estimate costs and outcomes. We argue that
our structural assumptions (mainly model structure and transition
probabilities) are reasonable because they are consistent with
local reality, the parsimony principle that facilitates knowledge
translation, and accepted by local experts. In addition, we believe
that when evidence aims to support decision-making, this should
not be postponed because of lack of evidence; instead, we
believe that the best available evidence should be pursued. As an
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example to this aim, expert elicitation methods were developed,
tested, and have been broadly discussed in the field of health
economics.
Despite the limitations described above, this study is the first to
show some of the main consequences and associated costs of
chronic pain in Chile, and to the best of our knowledge, one of the
few studies specifically designed to characterize costs and
consequences. These results confirm what has been widely
described in international literature, ie, chronic pain is a common
health problem causing severe disability and impacting quality of
life from many dimensions. This is especially interesting in Chile,
where many of the conditions included in this study can be
managed with health resources already included in the Chilean
health benefit plan. This suggests that the current practice is not
being sufficient to decrease the magnitude of this problem. We
hypothesize that this occurs because patients are being
managed focusing on the etiology of the disease, and pain is
addressed as a secondary symptom that is usually treated as if
was an acute episode of pain.
Future research needs to be performed to assess the
effectiveness of health programs to address chronic pain as the
main health problem. This considers clinical interventions but also
other more innovative strategies such as training patients how to
live with pain. The optimization of existing primary and secondary
care before implementing new health interventions such as
specialized pain centers, education of health professional to offer
better treatments in primary care, and the generation of clinical
guidelines are some examples of these type of strategies. If
effective programs can be implemented, the measurement of
their impact will benefit from this study as a baseline character-
ization of the problem.
Finally, the value of this piece of research is given partially by
the reported magnitudes but also by the methodological
approach used to produce this information; it provides a good
alternative to estimate legitimate results that are locally valid,
accepted, and could be used for decision-making.
5. Conclusion
There are important health and nonhealth consequences
associated with chronic pain, which are costly to health systems
and society as a whole and they impact negatively in an important
percentage of the population. More attention needs to be given to
this health problem not only because it is costly but also because
adequate pain treatment should be considered a human right,
and it is the health system’s responsibility to provide it.3,14
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